Mantle cell lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:52416C83.1
Who is this for?
Show terms as
5FDA treatments36Active trials82Specialists8Treatment centers3Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma, which is a cancer of the lymphatic system. It starts in a type of white blood cell called a B-cell, specifically in a region of the lymph node known as the 'mantle zone.' These abnormal B-cells grow out of control and can spread to lymph nodes, the spleen, bone marrow, the digestive tract, and other organs throughout the body. MCL is considered a rare but aggressive cancer, meaning it tends to grow and spread faster than some other lymphomas. The most common symptoms include swollen lymph nodes (often in the neck, armpits, or groin), fatigue, unexplained weight loss, night sweats, and a feeling of fullness or discomfort in the abdomen due to an enlarged spleen or liver. Some people also develop digestive problems if the cancer affects the gut. Treatment has improved significantly in recent years. Options include chemotherapy, targeted therapies, immunotherapy (such as rituximab), and stem cell transplants. Newer drugs like ibrutinib, acalabrutinib, and venetoclax have been approved by the FDA and have changed how MCL is managed. While MCL is generally not considered curable with standard therapy, many patients achieve long periods of remission. Research into new treatments is very active, giving patients and families reason for hope.

Also known as:

Key symptoms:

Swollen lymph nodes in the neck, armpits, or groinPersistent fatigue or low energyUnexplained weight lossDrenching night sweatsFever without a clear causeFeeling of fullness or bloating in the abdomenEnlarged spleen causing discomfort under the left ribsEnlarged liverDigestive problems such as diarrhea, abdominal pain, or blood in stoolFrequent infections due to a weakened immune systemShortness of breathItchy skinBone marrow involvement leading to low blood counts (anemia, easy bruising, or bleeding)

Clinical phenotype terms (9)— hover any for plain English
Abnormal bone marrow cell morphologyHP:0005561B-cell lymphomaHP:0012191
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
May 2026Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

M.D. Anderson Cancer Center — PHASE2

TrialNOT YET RECRUITING
Feb 2026CALQUENCE: New indication approved
FDAcompleted
Feb 2026CALQUENCE: New indication approved
FDAcompleted
Feb 2026A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Guangzhou Lupeng Pharmaceutical Company LTD. — PHASE3

TrialRECRUITING
Feb 2026PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

Fondazione Italiana Linfomi - ETS — PHASE2

TrialNOT YET RECRUITING
Dec 2025Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China — PHASE2

TrialNOT YET RECRUITING
Oct 2025Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment

Tianjin Medical University Cancer Institute and Hospital — PHASE2

TrialNOT YET RECRUITING
Sep 2025Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Ruijin Hospital — PHASE2

TrialRECRUITING
Sep 2025Clinical-instrumental Evaluation and Assessment of Return to Sports Activity in Patients Surgically Treated for Isolated "Stener-like" Lesions of the Medial Collateral Ligament (MCL) or in the Context of Multiligament Injuries and Articular Fractures

Stefano Zaffagnini

TrialRECRUITING
Sep 2025A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

AstraZeneca — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

5 available

Velcade

bortezomib· Takeda Pharmaceuticals U.S.A., Inc.

VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma

BRUKINSA

zanubrutinib· BeOne Medicines USA, Inc.Accelerated Approval

BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Jaypirca

pirtobrutinib· Loxo Oncology, Inc.Orphan Drug

treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor

CALQUENCE

acalabrutinib· Acerta Pharma, LLC (a member of the AstraZeneca Group)Orphan Drug

Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

TECARTUS�

brexucabtagene autoleucel· Kite Pharma, Inc.■ Boxed WarningOrphan Drug

TECARTUS� is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)

Clinical Trials

20 recruitingView all trials with filters →
Phase 36 trials
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Actively Recruiting
· Sites: Beijing, Beijing Municipality; Nanning, Guangxi · Age: 1899 yrs
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
Phase 3
Actively Recruiting
PI: Martin Dreyling, Prof. (Klinikum der Universität München) · Sites: Aalborg; Aarhus C +110 more · Age: 1865 yrs
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase 3
Actively Recruiting
· Sites: Beijing; Beijing +37 more · Age: 6099 yrs
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Phase 3
Actively Recruiting
PI: Study Director (BeOne Medicines) · Sites: Birmingham, Alabama; Phoenix, Arizona +147 more · Age: 1899 yrs
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Phase 3
Active
· Sites: Tucson, Arizona; Downey, California +226 more · Age: 6599 yrs
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Phase 3
Active
PI: Timothy S Fenske (ECOG-ACRIN Cancer Research Group) · Sites: Birmingham, Alabama; Anchorage, Alaska +373 more · Age: 1870 yrs
Phase 213 trials
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2
Actively Recruiting
PI: Yucai Wang (Academic and Community Cancer Research United) · Sites: Rochester, Minnesota; Houston, Texas · Age: 1899 yrs
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Phase 2
Actively Recruiting
· Sites: Guangzhou, Guangdong · Age: 1899 yrs
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Phase 2
Active
PI: Jonathon B. Cohen, MD, MS (Emory University) · Sites: Atlanta, Georgia; Atlanta, Georgia +1 more · Age: 1899 yrs
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2
Actively Recruiting
PI: Michael Wang, MD, MS (M.D. Anderson Cancer Center) · Sites: Rochester, Minnesota; Houston, Texas · Age: 1899 yrs
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2
Active
· Sites: Woolloongabba, Queensland; Bedford Park, South Australia +1 more · Age: 1899 yrs
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Phase 2
Active
· Sites: Hackensack, New Jersey; Stony Brook, New York +27 more · Age: 1899 yrs
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Phase 2
Actively Recruiting
PI: Stephen D Smith (Academic and Community Cancer Research United) · Sites: New Orleans, Louisiana; Minneapolis, Minnesota +5 more · Age: 1875 yrs
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality · Age: 1499 yrs
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Phase 2
Active
PI: Evanthia Galanis, MD (Alliance Foundation Trials, LLC.) · Sites: Duarte, California; Baltimore, Maryland +7 more · Age: 1899 yrs
Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL
Phase 2
Active
PI: Qingqing Cai, MD (Sun Yat-Sen University Cancer Center) · Sites: Guangzhou, Guangdong; Guangzhou, Guangdong +1 more · Age: 1875 yrs
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Phase 2
Active
PI: Acerta Pharma (1-888-292-9613) · Sites: Tampa, Florida; Chicago, Illinois +56 more · Age: 1899 yrs
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Phase 2
Actively Recruiting
PI: Marco Ladetto (S.C. Ematologia - A.S.O. "SS Antonio e Biagio e Ce) · Sites: Brescia, Italy; Alessandria +19 more · Age: 1879 yrs
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2
Active
PI: Nina D Wagner-Johnston (ECOG-ACRIN Cancer Research Group) · Sites: Anchorage, Alaska; Anchorage, Alaska +502 more · Age: 1870 yrs
Other1 trial
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Actively Recruiting
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Milwaukee, Wisconsin · Age: 1899 yrs

Specialists

Showing 25 of 82View all specialists →
CM
Carlo Visco, MD
Specialist
PI on 2 active trials
JL
Jason J Luke
Philadelphia, Pennsylvania
Specialist

Rare Disease Specialist

PI on 4 active trials
WM
Wyndham H Wilson, M.D.
BETHESDA, MD
Specialist
PI on 8 active trials
PM
Paolo Caimi, MD
CLEVELAND, OH
Specialist
PI on 5 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
CD
Catherine S Diefenbach
NEW YORK, NY
Specialist
PI on 4 active trials1 Mantle cell lymphoma publication
RM
Rahul Banerjee, MD
SEATTLE, WA
Specialist
PI on 2 active trials
AP
Andrew Zelenetz, MD, PhD
NEW YORK, NY
Specialist
PI on 3 active trials
PM
Paul Martin
Specialist
PI on 3 active trials73 Mantle cell lymphoma publications
MM
Matthew Davids, MD
BOSTON, MA
Specialist
PI on 1 active trial
CP
Claudio G. Brunstein, MD, PhD
MINNEAPOLIS, MN
Specialist
PI on 6 active trials
EM
Evanthia Galanis, MD
ROCHESTER, MN
Specialist
PI on 9 active trials
JM
Jennifer Amengual, MD
NEW YORK, NY
Specialist
PI on 2 active trials
MM
Margaret L. MacMillan, MD
Specialist
PI on 4 active trials
JP
James L. Rubenstein, MD, PhD
Specialist
PI on 2 active trials
KF
Keith T Flaherty
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial2 Mantle cell lymphoma publications
LS
Lecia V Sequist
Philadelphia, Pennsylvania
Specialist

Rare Disease Specialist

PI on 1 active trial
JM
Jonathan Friedberg, MD
HOUSTON, TX
Specialist
PI on 2 active trials
FP
Fabrice Jardin, MD, PhD
Specialist
PI on 1 active trial
SG
Steven Le Gouill
Specialist
PI on 2 active trials

Treatment Centers

8 centers
⚗️ Trial Site

University of Alabama at Birmingham Cancer Center

📍 Birmingham, Alabama

⚗️ Trial Site

Kingman Regional Medical Center

📍 Kingman, Arizona

⚗️ Trial Site

Cancer Center at Saint Joseph's

📍 Phoenix, Arizona

⚗️ Trial Site

Fairbanks Memorial Hospital

📍 Fairbanks, Alaska

⚗️ Trial Site

University of South Alabama Mitchell Cancer Institute

📍 Mobile, Alabama

⚗️ Trial Site

Mayo Clinic Hospital in Arizona

📍 Phoenix, Arizona

⚗️ Trial Site

Mayo Clinic in Arizona

📍 Scottsdale, Arizona

⚗️ Trial Site

Mobile Infirmary Medical Center

📍 Mobile, Alabama

Financial Resources

3 resources
Jaypirca(pirtobrutinib)Loxo Oncology, Inc.
CALQUENCE(acalabrutinib)Acerta Pharma, LLC (a member of the AstraZeneca Group)

Breyanzi

Juno Therapeutics, Inc.

Unverified — confirm before calling
copay card
copay assistancePatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Mantle cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Mantle cell lymphomaForum →

No community posts yet. Be the first to share your experience with Mantle cell lymphoma.

Start the conversation →

Latest news about Mantle cell lymphoma

5 articles
NewsLEUKEMIAApr 22, 2026
PRMT5 inhibition sensitizes B-cell lymphoma cells to ferroptosis.
Protein arginine methyltransferase 5 (PRMT5) is overexpressed in B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL
NewsTRANSPLANTATION AND CELLULAR THERAPYApr 19, 2026
Austrian real-world experience with standard of care brexucabtagene autoleucel in patients with relapsed or refractory mantle-cell lymphoma.
Mantle-cell lymphoma (MCL) represents a rare B-cell malignancy with a challenging treatment situation in the case of relapsed or refractory (r/r) disease. Brexu
NewsCANCERApr 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 2025 brought together a multidisciplinary group of oncology experts
NewsTRANSPLANTATION AND CELLULAR THERAPYApr 8, 2026
Understanding Hodgkin and B-Cell Non-Hodgkin Lymphoma Progression in Patients Awaiting Autologous Transplant in a Resource-Constrained Setting.
Wait times for autologous hematopoietic cell transplantation (auto-HCT) are often prolonged in resource-constrained countries due to logistical and social limit
NewsJOURNAL OF GASTROINTESTINAL SURGERY : OFFICIAL JOURNAL OF THE SOCIETY FOR SURGERY OF THE ALIMENTARY TRACTMar 21, 2026
Gastrointestinal mantle cell lymphoma.
Gastrointestinal mantle cell lymphoma.
See all news about Mantle cell lymphoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my MCL and what does that mean for my treatment options?,Do my cancer cells have any high-risk features like TP53 mutations, and how does that affect my prognosis?,Am I a candidate for stem cell transplant, and should that be part of my treatment plan?,What are the differences between the chemotherapy regimens and targeted therapies available to me, and which do you recommend for my situation?,Are there any clinical trials I should consider?,What signs or symptoms should prompt me to call your office or go to the emergency room right away?,What support services — such as social work, nutrition counseling, or mental health support — are available to me and my family?

Common questions about Mantle cell lymphoma

What is Mantle cell lymphoma?

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma, which is a cancer of the lymphatic system. It starts in a type of white blood cell called a B-cell, specifically in a region of the lymph node known as the 'mantle zone.' These abnormal B-cells grow out of control and can spread to lymph nodes, the spleen, bone marrow, the digestive tract, and other organs throughout the body. MCL is considered a rare but aggressive cancer, meaning it tends to grow and spread faster than some other lymphomas. The most common symptoms include swollen lymph nodes (often in the neck, armpits, or groin

How is Mantle cell lymphoma inherited?

Mantle cell lymphoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Mantle cell lymphoma typically begin?

Typical onset of Mantle cell lymphoma is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Mantle cell lymphoma?

Yes — 20 recruiting clinical trials are currently listed for Mantle cell lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Mantle cell lymphoma?

25 specialists and care centers treating Mantle cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Mantle cell lymphoma?

3 patient support programs are currently tracked on UniteRare for Mantle cell lymphoma. See the treatments and support programs sections for copay assistance, eligibility, and contact details.